Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System

Abbott Labs (ABT) PT Raised to $63 at Stifel Following 3Q Release

October 18, 2017 5:06 PM EDT

Stifel raised its price target on Abbott Labs (NYSE: ABT) to $63.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. The company reported above-expectation 5.6% comparable operational sales growth and above-consensus EPS at $0.66 (vs. $0.65 Consensus). positive 3Q highlights included: key product approvals, improving pipeline... More